Schonfeld Strategic Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-234,294	Closed	-$549K	–	3220
2022 Q3	$549K	Buy	234,294 +79,566	+51%	+$282K	﹤0.01%	1687
2022 Q2	$469K	Buy	154,728 +13,638	+10%	+$66.3K	﹤0.01%	1401
2022 Q1	$958K	Sell	141,090 -13,100	-8%	-$93.4K	0.01%	1017
2021 Q4	$1.29M	Buy	154,190 +37,406	+32%	+$308K	0.01%	820
2021 Q3	$867K	Sell	116,784 -13,228	-10%	-$81.9K	0.01%	1012
2021 Q2	$885K	Sell	130,012 -78,800	-38%	-$655K	0.01%	969
2021 Q1	$2.14M	Buy	+208,812	New	+$2.29M	0.03%	646
2018 Q2	–	Sell	-22,280	Closed	-$498K	–	1029
2018 Q1	$498K	Buy	+22,280	New	+$494K	0.04%	479

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Schonfeld Strategic Advisors's JNCE Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 234,294 shares — an estimated $549K sold.

Schonfeld Strategic Advisors first reported a position in JNCE in Q1 2018 and held it in 8 quarters. The position peaked at $2.14M in Q1 2021. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

Schonfeld Strategic Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 234,294 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $549K.
Schonfeld Strategic Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 8 quarters.
Schonfeld Strategic Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $2.14M in Q1 2021.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.